Providing-world class operational expertise, logistical infrastructure, and the scientific rigor needed to effectively characterize, research, and treat infectious diseases as they emerge.
We deploy an expert global team who can utilize their experience, knowledge, and the best technologies available to accelerate clinical trials to ultimately reduce the burden of infectious disease. We do this empowered by our people, science, and technology and infrastructure.
Throughout the years Cerba Research established an impressive track record by supporting studies in all phases of vaccine development, with innovative pre-clinical models and customized clinical models. A wide range of assays are available to test vaccine safety, efficacy, immune toxicology and pharma kinetics.
The latest integrated laboratory techniques allow for high-through put analysis. Our assay portfolio includes:
• Best in class molecular assays: Quantitative Real Time PCR and Next, Gen Sequencing
• State of the art immunological assays,including antibody and cell mediated immunity assays (ELISPOT, flow cytometry)
• High quality serology
• Novel research techniques including the in-house developed VirospotTM
your partner in vaccine development
At Cerba Research, we offer a range of virology /immunology and molecular diagnostic assays for the testing and development of new and effective vaccines. We can carry out the necessary laboratory analysis of clinical samples and analyze the results on your behalf, reporting these results back to you in formats that comply with the requirements of regulatory authorities, such as the FDA and EMA.
With extensive experience in analyzing complex datasets, including next-generation sequencing, we are proud to offer customized solutions to streamline and enhance your data reporting process for vaccination testing.
Through extensive collaboration with diagnostic and (bio)pharmaceutical companies in the field of molecular testing regarding new vaccines (Rotavirus, HPV), we can help enhance the clinical vaccine development.
Experience With Relevant Viral Diseases
We have distinct experience with viral targets such as:
- Human papillomavirus (HPV)
- Hepatitis viruses (HBV and HCV)
- Herpesviruses (CMV, EBV, VZV, HSV)
- Respiratory infections (RSV, Rhinovirus and Influenza virus)
And other targets, including:
A unique footprint in South Africa
Our South African facilities and capabilities have been established for over 25 years. With offices in Durban, Cape Town and Johannesburg we are uniquely positioned to respond to emerging trends in Infectious Disease, on the African continent. Collaborating with Government Health Agencies, Not for Profit, and Clinical Research Organisations from routine testing to specialized testing includes:
- Safety Laboratory
- PBMC Processing
- Speciality Molecular Testing
- Tuberculosis P3 Laboratory
- Biobanking Facility
Reach out to our experts and see how we can help you advance your clinical trial in the field of infectious diseases and vaccine developmentContact Us